Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sebastian

Showing results (111-120 of 183) with videos related to

Pageof 19
Sort By:
The American Journal of Cardiology|May 13, 2017
Evolution of Australian Percutaneous Coronary Intervention (from the Melbourne Interventional Group [MIG] Registry)Julian Yeoh, Matias B Yudi, Nick Andrianopoulos, et al.
The Annals of Pharmacotherapy|November 27, 2019
Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary InterventionRochelle M Gellatly, Cia Connell, Christianne Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2018
Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional StudyMarlene Hechtner, Martin Eichler, Beatrice Wehler, et al.
The Medical Journal of Australia|October 4, 2006
Use of drug-eluting stents in Victorian public hospitalsBryan P Yan, Andrew E Ajani, Stephen J Duffy, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
The American Journal of Cardiology|June 20, 2021
Comparison of Outcomes of Coronary Artery Disease Treated by Percutaneous Coronary Intervention in 3 Different Age Groups (<45, 46-65, and >65 Years)Samer Noaman, Diem Dinh, Christopher M Reid, et al.
Leukemia Research|August 25, 2019
Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failureJan Stratmann, Elisabeth van Kann, Christoph Rummelt, et al.
Heart, Lung & Circulation|March 1, 2023
Trends and Real-World Safety of Patients Undergoing Percutaneous Coronary Intervention for Symptomatic Stable Ischaemic Heart Disease in AustraliaGarry W Hamilton, Julian Yeoh, Diem Dinh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 studyMartin Sebastian, Philipp Kiewe, Wolfgang Schuette, et al.
Pageof 19

Showing results (111-120 of 183) with videos related to

Sort By:
Pageof 19
The American Journal of Cardiology|May 13, 2017
Evolution of Australian Percutaneous Coronary Intervention (from the Melbourne Interventional Group [MIG] Registry)Julian Yeoh, Matias B Yudi, Nick Andrianopoulos, et al.
The Annals of Pharmacotherapy|November 27, 2019
Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary InterventionRochelle M Gellatly, Cia Connell, Christianne Tan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2018
Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional StudyMarlene Hechtner, Martin Eichler, Beatrice Wehler, et al.
The Medical Journal of Australia|October 4, 2006
Use of drug-eluting stents in Victorian public hospitalsBryan P Yan, Andrew E Ajani, Stephen J Duffy, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
The American Journal of Cardiology|June 20, 2021
Comparison of Outcomes of Coronary Artery Disease Treated by Percutaneous Coronary Intervention in 3 Different Age Groups (<45, 46-65, and >65 Years)Samer Noaman, Diem Dinh, Christopher M Reid, et al.
Leukemia Research|August 25, 2019
Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failureJan Stratmann, Elisabeth van Kann, Christoph Rummelt, et al.
Heart, Lung & Circulation|March 1, 2023
Trends and Real-World Safety of Patients Undergoing Percutaneous Coronary Intervention for Symptomatic Stable Ischaemic Heart Disease in AustraliaGarry W Hamilton, Julian Yeoh, Diem Dinh, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 studyMartin Sebastian, Philipp Kiewe, Wolfgang Schuette, et al.
Pageof 19